Medical Marijuana, Inc. Reports First Quarter 2017 Financial Results and Operational Highlights

– The increase in the net comprehensive income is mostly derived from the Company’s unrealized gains from its holdings in AXIM Biotechnologies. Portfolio company Kannaway showed increased revenue from $305,670 in Q1 2016 to $1,741,553 in Q1 2017, an increase of 469%.

“We are pleased to see certain management re-structuring efforts rewarded after the company made changes in 2016,” said Medical Marijuana, Inc. Dr. Stuart Titus. “We believe that our revenue and sales velocities have the ability to maintain their current momentum. We have had significant investment portfolio appreciation in terms of unrealized gains in the past year and expect ‘market-average’ performance in the future. We are satisfied with where operations currently sit and believe that in the coming years we will see other investments and company divisions adding nice value for the company and its shareholders.”

Titus added, “Further, we continue to be encouraged by the growing international acceptance of cannabis and the progress our team has made in educating the world on its many therapeutic uses. I am quite excited about international expansion opportunities. We are thankful for our dedicated team and the continued support of our shareholders.”


Medical Marijuana, Inc. investments and subsidiaries continued international expansion and product development in the first quarter of 2017.

1) HempMedsR

Wholly-owned subsidiary HempMeds US, the portfolio’s predominate consumer brand, continued to experience growth in 2017 and experienced the following milestones:

2) HempMeds BrazilR

93.4%-owned subsidiary HempMeds Brazil, which received the country’s first import permit for cannabis products, achieved the following milestones in the first quarter of 2017:

3) HempMeds MexicoR

Wholly-owned subsidiary HempMeds Mexico, which accomplished the first-ever import permits for a cannabis product for its RSHO™ and RSHO-X™ products from the federal governments of Mexico and Paraguay in 2016, achieved the following milestones in the first quarter of 2017:

4) KannawayR

Subsidiary Kannaway, a premier hemp lifestyle brand, recently experienced 11-times revenue growth in a year-over-year comparison, and achieved the following milestones in the first quarter of 2017:


1) AXIM BiotechnologiesR

AXIM Biotechnologies (OTCQB: AXIM) is a cannabinoid research and development biotech company. Medical Marijuana, Inc. owns 22,669,100 shares worth approximately $308,704,704. The closing share price was $13.44 as of March 31, 2017, which is an increase of $13.04 from $0.40 as of March 31,2016. AXIM Biotechnologies achieved the following milestones:

2) Kannalife Sciences

Kannalife Sciences Inc. is an early-stage biotechnology company involved with the pharmaceutical development of new therapeutic compounds based on cannabinoids, which Medical Marijuana, Inc. owns 16.7% of. Kannalife has garnered a licensing agreement with the United States National Institutes of Health (NIH) for two indications: (1) Hepatic Encephalopathy (HE) and secondly for traumatic head injury, known as (2) Chronic Traumatic Encephalopathy (CTE).


Legal cannabis is arguably the fastest growing industry worldwide.


Gross Revenue: Q1 2016 – $1,535,728Q1 2017 – $3,612,739

Gross Profit: Q1 2016 – $820,446Q1 2017 – $2,545,229

Net Income/Loss:Q1 2016 – ($11,096,659)Q1 2017 – ($2,222,818)

Net Comprehensive Income:Q1 2016 – ($9,708,598)Q1 2017 – $105,632,830

Total assets: Q1 2016 – $214,115,665Q1 2017 – $494,182,096

About Medical Marijuana, Inc.

We are a company of firstsR. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

To see Medical Marijuana, Inc.’s video statement, click here.

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.


Public Relations Contact:

Andrew HardChief Executive OfficerCMW MediaP: 888-829- 0070[email protected]

Photo – – –

(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)